Press Releases Items Per Page 102550 Year None2018201720162015201420132012201120102007 07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 05.24.17 Syndax Prices Public Offering of Common Stock 05.23.17 Syndax Announces Proposed Public Offering of Common Stock 05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma 05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 05.15.17 Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference 05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update 05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017 04.27.17 Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer 04.20.17 Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 04.04.17 Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors 03.29.17 Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update
05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
04.27.17 Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer
04.20.17 Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
04.04.17 Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
03.29.17 Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
